Clinical Trial-Clinical Trial Center, Kaohsiung Medical University Chung-Ho Memorial Hospital

Trial Section

  Home / Trial Section / Clinical Trial
Indication Department Study Title Study Phase Investigator Contact Person Status
角膜塑型 Ophthalmology Infinite Overnight Orthokeratology Contact Lenses Clinical Study Class III Shiuh-Liang Hsu 李貞德 On-going
Nephrology A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria Phase III Yi-Wen Chiu 陳宜霈 On-going
Non-Small Cell Lung Cancer Chest Medicine A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50% Phase III Jen-Yu Hung 董俞君 On-going
MAC-LD Chest Medicine A Phase 2/3, Multicenter, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) Phase II Hung Ling Huang 杜玟蓉 On-going
Gastric Cancer Gastroenterology A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 Phase III I-Chen Wu 郭靜芳 On-going
Hepatitis Hepatobiliary and Pancreatic Medicine A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of AHB-137 with Single Ascending Doses and Multiple Doses in Healthy Volunteers and Initial Efficacy in Chronic Hepatitis B Patients Phase I Wan-Long Chuang 莊心婷 On-going
Lung Cancer Chest Medicine SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≧50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression Phase III Jen-Yu Hung 周婉明 On-going
Gastric Cancer Gastroenterology A randomized, multicenter, double-blind, phase II study to compare the efficacy and safety of the treatment with ONO-4578 in combination with nivolumab, fluoropyrimidine-based and platinum-based chemotherapy (hereinafter referred to as chemotherapy) with those of the treatment with placebo in combination with nivolumab and chemotherapy in chemotherapy-naive participants with human epidermal growth factor receptor 2 (HER2)-negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) Phase II I-Chen Wu 郭靜芳 On-going
Multiple Myeloma Hematology and Oncology An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; anti-BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory Multiple Myeloma (LINKER-MM3) Phase III Shih-Feng Cho On-going
Head and Neck Cancer Hematology and Oncology A Single Arm, Open label, Phase 1b Study of Xevinapant in Combination With Weekly Cisplatin and Intensity-modulated Radiotherapy to Assess Safety and Tolerability in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy Phase I Hui-Ching Wang 俞念廷 On-going

 ←   Please slide to the left for more information